STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors
Phase IV Clinical Trial
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)